<DOC>
	<DOCNO>NCT00054899</DOCNO>
	<brief_summary>EP2101 new cancer vaccine contain 10 different peptide antigen . The vaccine design activate immune system develop response tumor cell order delay prevent recurrence cancer . This study test safety measure level immune stimulate capability EP2101 patient Non-Small Cell Lung Cancer .</brief_summary>
	<brief_title>An Open Label Study Peptide Vaccine Patients With Stage IIb IIIa Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Confirmed diagnosis NonSmall Cell Lung Cancer , stage IIb IIIa At least four week follow prior standard treatment , evidence disease Must use adequate birth control Prior cancer vaccine therapy concurrent participation investigational study A history HIV , Hepatitis B C , acute medical condition may compromise patient safety activity study vaccine treatment A history adverse reaction follow administration vaccine , history hypersensitivity component study vaccine Women pregnant , intend become pregnant , breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2004</verification_date>
	<keyword>vaccine</keyword>
	<keyword>lung</keyword>
	<keyword>cancer</keyword>
	<keyword>Carcinoma , Large Cell</keyword>
	<keyword>Non-Small-Cell Lung Carcinoma</keyword>
</DOC>